Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autolus Therapeutics plcAUTL · Entity 1933 | Director | June 29, 2026 | July 01, 2026 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 10, 2026 | June 12, 2026 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | April 26, 2022 | April 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autolus Therapeutics plc
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 31,667 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29 | Direct | 47,500 |
Reported balance
After 2026-06-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
F2: The RSUs vest in one installment on June 29, 2027.
F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.
Praxis Precision Medicines, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,269 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 3,269 F1: Mr. Young was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10 | Direct | 648 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Young was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Theravance Biopharma, Inc.
Report date April 26, 2022 · Filed April 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 78,010 |
Reported balance
After 2022-04-26 transaction · row 1
1 source rowRow 1 · 2022-04-26 · Grant · Acquired 9,852 · Balance 78,010 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 28,000 |
Reported balance
After 2022-04-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-26 · Grant · Acquired 28,000 · Balance 28,000 F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VERTEX PHARMACEUTICALS INC / MA
Report date June 01, 2020 · Filed June 03, 2020
Section 16 reporting ended · disclosed 2020-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $286.27 · Expires 2030-05-31 | Direct | 4,527 |
Reported balance
After 2020-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-01 · Grant · Acquired 4,527 · Balance 4,527 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jul 1, 2026 20:21 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantShare Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001730463-26-000107 · form4.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:21 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantRestricted Share Units · Derivative | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001730463-26-000107 · form4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:24 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 648 | $0.00 Strike: $240.66 | $0.00 |
DisclosureSEC source: 0001689548-26-000062 · wk-form4_1781299452.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648 Underlying: Common Stock · 648 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:24 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 1,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-26-000062 · wk-form4_1781299452.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269 F1 · kind: Mr. Young was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 20:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 10,520 | $0.00 Strike: $44.04 | $0.00 |
DisclosureSEC source: 0001689548-25-000080 · wk-form4_1751057715.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2035-06-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 8,566 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001689548-24-000075 · wk-form4_1717714526.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 11:13 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 28,981 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001689548-23-000109 · wf-form4_168674119773018.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,981 Underlying: Common Stock · 28,981 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:25 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 22,753 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001689548-22-000064 · wf-form4_165368670859170.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,753 Underlying: Common Stock · 22,753 shares Expires 2032-05-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on May 26, 2022. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001415889-22-004339 · form4-04282022_060430.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004339 · form4-04282022_060430.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,010 Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:03 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 22,343 | $0.00 Strike: $20.42 | $0.00 |
DisclosureSEC source: 0001689548-21-000060 · wf-form4_162327257160147.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Underlying: Common Stock · 22,343 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 8, 2021. Read SEC document |
| May 13, 2021 Filed Jul 7, 2021 21:16 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | OtherCommon Stock | 28,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-21-000069 · wf-form4_162569259680052.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,473 F1 · kind: Pro rata distribution from Clarus Lifesciences III, L.P., of which the reporting person is a limited partner. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004705 · edgar.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004705 · edgar.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,158 Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034055 · doc4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005307 · edgar.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005307 · edgar.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,330 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · derivative · entry 6 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $220.08 | $22,008.00 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · nonDerivative · entry 5 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,311 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,134 | $219.37 | $2,223,095.58 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · nonDerivative · entry 4 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,411 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $219.37 (range $219.08 to $219.78). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,266 | $218.73 | $1,589,292.18 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · nonDerivative · entry 3 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,545 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $218.73 (range $218.08 to $219.07). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $217.72 | $544,300.00 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · nonDerivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,811 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $217.72 (range $217.08 to $218.06). F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $72.14 | $1,442,800.00 |
DisclosureSEC source: 0001209191-20-001775 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $65.65 | $0.00 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · derivative · entry 6 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $221.16 | $66,348.00 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · nonDerivative · entry 5 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,311 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $221.16 (range $221.09 to $221.30). Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $220.25 | $110,125.00 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · nonDerivative · entry 4 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,611 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $220.25 (range $219.90 to $220.73). Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 21,798 | $218.93 | $4,772,236.14 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · nonDerivative · entry 3 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,111 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $218.93 (range $218.50 to $219.47). Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,402 | $218.05 | $1,614,006.10 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · nonDerivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,909 F1 · kind: Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $218.05 (range $217.50 to $218.49). F3 · price: Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $65.65 | $1,969,500.00 |
DisclosureSEC source: 0001209191-20-000298 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-034251 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,311 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001179110-19-005472 · edgar.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005472 · edgar.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,695 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,229 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0001209191-18-035701 · doc4.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Underlying: Common Stock · 3,229 shares Expires 2028-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035701 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,930 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006197 · edgar.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006197 · edgar.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,310 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0001209191-17-037916 · doc4.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Common Stock · 5,295 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037916 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,129 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007547 · edgar.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,124 Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 7,073 | $0.00 Strike: $93.51 | $0.00 |
DisclosureSEC source: 0001209191-16-125727 · doc4.xml · derivative · entry 2 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,073 Underlying: Common Stock · 7,073 shares Expires 2026-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,941 | $0.01 | $29.41 |
DisclosureSEC source: 0001209191-16-125727 · doc4.xml · nonDerivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $127.54 | $0.00 |
DisclosureSEC source: 0001209191-15-049660 · doc4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038675 · doc4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2014 Filed May 9, 2014 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $65.65 | $0.00 |
DisclosureSEC source: 0001209191-14-032611 · doc4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2024-05-06 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/07/2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.